TCRX

TCRX

USD

TScan Therapeutics Inc. Common Stock

$1.120-0.050 (-4.274%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.170

Hoch

$1.250

Tief

$1.080

Volumen

0.81M

Unternehmensfundamentaldaten

Marktkapitalisierung

63.6M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.51M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $1.02Aktuell $1.120Hoch $6.225

Ähnliche Nachrichten

Analyst Upgrades

BTIG Downgrades TScan Therapeutics to Neutral

BTIG analyst Justin Zelin downgrades TScan Therapeutics from Buy to Neutral.

Mehr anzeigen
BTIG Downgrades TScan Therapeutics to Neutral
Analyst Upgrades

Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6

Needham analyst Gil Blum maintains TScan Therapeutics with a Buy and lowers the price target from $9 to $6.

Mehr anzeigen
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
GlobeNewswire

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;

Mehr anzeigen
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.